Rossby Financial LCC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Rossby Financial LCC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,769 shares of the medical research company’s stock, valued at approximately $920,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Nordea Investment Management AB grew its stake in shares of Thermo Fisher Scientific by 23.6% in the 4th quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company’s stock valued at $28,868,000 after buying an additional 10,606 shares in the last quarter. S.E.E.D. Planning Group LLC lifted its stake in shares of Thermo Fisher Scientific by 6.2% in the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company’s stock valued at $5,528,000 after purchasing an additional 618 shares during the last quarter. Czech National Bank increased its position in Thermo Fisher Scientific by 6.6% during the fourth quarter. Czech National Bank now owns 82,934 shares of the medical research company’s stock worth $43,145,000 after buying an additional 5,118 shares during the last quarter. Douglas Lane & Associates LLC lifted its position in shares of Thermo Fisher Scientific by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 182,511 shares of the medical research company’s stock worth $94,948,000 after buying an additional 3,460 shares during the last quarter. Finally, M&T Bank Corp boosted its stake in shares of Thermo Fisher Scientific by 4.2% during the 3rd quarter. M&T Bank Corp now owns 113,347 shares of the medical research company’s stock worth $70,113,000 after acquiring an additional 4,584 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This represents a 1.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 in the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 2.4 %

NYSE TMO opened at $437.91 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 52 week low of $409.85 and a 52 week high of $627.88. The stock has a market capitalization of $165.21 billion, a P/E ratio of 26.49, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The stock has a fifty day moving average of $510.56 and a 200-day moving average of $538.78.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMO. Raymond James reaffirmed an “outperform” rating and set a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Citigroup dropped their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a report on Friday, January 31st. Morgan Stanley raised their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Finally, UBS Group boosted their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.